NCT01241461已完成1 期
A Phase 1 Study of LY2584702 in Japanese Patients With Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Number of Participants With Clinically Significant Effects
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability of LY2584702 in Japanese patients with advanced and/or metastatic solid tumors for which no proven effective therapy exists.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer (solid tumors) that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists.
- •Have the presence of disease amenable to efficacy assessment as defined by the Response Evaluation Criteria In Solid Tumors (RECIST). Japanese patients who have advanced non-measurable disease with elevation of a validated tumor marker may be eligible, if discussed and agreed upon by the investigator and Lilly.
- •Have adequate organ function including:
- •Hematologic: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/liter (L), platelets greater than or equal to 100 x 10^9/L, and hemoglobin greater than or equal to 9 gram/deciliter (g/dL) (transfusions are not allowed prior to enrollment within 2 weeks).
- •Hepatic: Bilirubin less than or equal to 1.5 times upper limit of normal (ULN), alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN, or 5 times ULN for patients with hepatic metastases. Patients with bone metastases may enter with alkaline phosphatase values less than 5 times ULN, as long as other hepatic parameters meet inclusion criteria.
- •Renal: Serum creatinine less than or equal to 1.5 times ULN.
- •Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group scale
- •Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy prior to study enrollment and recovered from the acute effects of therapy.
- •Have an estimated life expectancy of 12 weeks or greater
- •Are able to swallow capsules
排除标准
- •Have received treatment within 4 weeks of the initial dose of study drug with a drug that has not received regulatory approval for any indication.
- •Have serious preexisting medical conditions or serious concomitant systemic disorders that, in the opinion of the investigator, would preclude participation in this study.
- •Prior clinical history of tuberculosis (patient doubt tuberculosis is screening required), and positive test results in hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb) (screening required).
- •Have symptomatic central nervous system (CNS) malignancy or metastasis. Patients with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Screening of asymptomatic patients without history of CNS metastasis is not required.
- •Have hematologic malignancies, or lymphoma.
研究组 & 干预措施
LY2584702
Experimental
干预措施: LY2584702 (Drug)
结局指标
主要结局
Number of Participants With Clinically Significant Effects
时间窗: Baseline through 30 days
A clinically significant effect was any event that was a dose-limiting toxicity event (DLT). DLT was defined as an adverse event related to LY2584702 during Cycle 1 (Day 1 to Day 30) that fulfills any one of the following criteria; Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 non-hematological toxicity; platelet count \<50.0 x 10\^9/Liter (L) with bleeding; CTCAE Grade 4 platelet count decreased; neutrophil count \<0.5 x 10\^9/L lasting for 5 days or longer; any febrile neutropenia; CTCAE Grade 4 anemia; participant risk due to increasing toxicity.
次要结局
- Number of Participants With Tumor Response(Baseline to study completion up to Day 183)
- Pharmacokinetics: Area Under the Concentration Time Curve (AUC) of LY2584702(Cycle 1 Day 1: Predose, 0.5,1,2,3,5,8,12 hours; Cycle 1 Day 2:24 and 36 hours; Cycle 1 Day 3: Predose sample (before first dose on day 3); Cycle 1 Day 10: Predose,0.5,1,2,3,5,8,12 hours;Cycle 1 Day 17: Predose;Cycle 1 Day24: Predose;Cycle 2 Day 1: Predose)
- Pharmacokinetics: Maximum Concentration (Cmax) of LY2584702(Cycle 1 Day 1: Predose, 0.5,1,2,3,5,8,12 hours; Cycle 1 Day 2:24 and 36 hours; Cycle 1 Day 3: Predose sample (before first dose on day 3); Cycle 1 Day 10: Predose,0.5,1,2,3,5,8,12 hours;Cycle 1 Day 17: Predose;Cycle 1 Day24: Predose;Cycle 2 Day 1: Predose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY2875358 in Japanese Participants With Advanced CancerSolid TumorsCarcinoma, Non-Small-Cell LungLymphomaNCT01602289Eli Lilly and Company17
未知
1 期
A Phase 1 Study of LY2584702 in Japanese Patients with Solid TumorsCancerJPRN-jRCT2080221292Eli Lilly Japan K.K.
已完成
1 期
A Study of LY2835219 in Japanese Participants With Advanced CancerNeoplasm MetastasisLymphomaNCT02014129Eli Lilly and Company12
已完成
1 期
A Study of LY2940680 in Japanese Participants With Advanced CancersNeoplasm MetastasisNCT01919398Eli Lilly and Company19
已完成
1 期
A Study of LY3023414 in Japanese Participants With Advanced CancerNeoplasmNCT02536586Eli Lilly and Company12